CS585
Cardiovascular Disease (Thrombosis prevention, Pulmonary Hypertension)
PreclinicalActive; Preclinical development ongoing
Key Facts
Indication
Cardiovascular Disease (Thrombosis prevention, Pulmonary Hypertension)
Phase
Preclinical
Status
Active; Preclinical development ongoing
Company
About Cereno Scientific
Cereno Scientific is a clinical-stage biotech focused on developing first-in-class, disease-modifying treatments for rare cardiovascular and pulmonary diseases with high unmet need. The company's strategy leverages orphan drug designations and accelerated pathways to efficiently advance its dual-platform pipeline, led by Phase II candidate CS1 for Pulmonary Arterial Hypertension (PAH). With a Phase II asset, a Phase I candidate, and a preclinical program, Cereno is positioned for value inflection through clinical milestones and potential partnerships.
View full company profile